Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene's PD-1 Antibody Approved in China to Treat Hodgkin's Lymphoma

publication date: Dec 30, 2019

BeiGene, a Beijing company developing targeted and immunoncology therapies, reported China has approved its anti-PD-1 antibody to treat classical Hodgkin’s lymphoma. It is indicated for CHL patients who have received has received at least two prior therapies. In a China Phase II trial, tislelizumab produced an objective response rate of 77% and a 62 % complete response rate. The PD-1 molecule is BeiGene's first drug approved in China; earlier, the US approved Brukinsa, BeiGene's BTK inhibitor, for mantle cell lymphoma (MCL). More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.